Pharmacogenomics: Hope or Hype?
- 31 October 2000
- journal article
- editorial
- Published by Elsevier in International Journal of Cardiology
- Vol. 76 (1) , 1-3
- https://doi.org/10.1016/s0167-5273(00)00419-8
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controlsThe Lancet, 2000
- Technologies for detecting genetic polymorphisms in pharmacogenomicsMolecular Diagnosis, 1999
- Prognostic significance of diabetes in acute myocardial infarction. Are the differences linked to female gender?International Journal of Cardiology, 1999
- Psychosocial and clinical factors predicting resumption of work following acute myocardial infarction in Japanese menInternational Journal of Cardiology, 1999
- Heart failure 99 — the Moxcon storyInternational Journal of Cardiology, 1999
- D allele of the angiotensin-converting enzyme gene is a risk factor for secondary cardiac events after myocardial infarctionInternational Journal of Cardiology, 1999
- Prognostic significance of diabetes in acute myocardial infarction. Are the differences linked to female gender?International Journal of Cardiology, 1999
- Pharmacogenomics - it's not just pharmacogeneticsCurrent Opinion in Biotechnology, 1998
- PharmacogenomicsCurrent Opinion in Nephrology and Hypertension, 1998
- Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarctionNature, 1992